The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Stuart A. Montgomery

University of London

UK

[email]@samontgomery.co.uk

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • University of London, UK. 2011
  • Imperial College School of Medicine, London, England, UK. 2008 - 2009
  • Imperial College School of Medicine, University of London, London bLudwig Maximilians University, Munich, UK. 2002 - 2009
  • PO Box 8751, London W13 8WH, UK. 2008

References

  1. Efficacy of escitalopram compared to citalopram: a meta-analysis. Montgomery, S., Hansen, T., Kasper, S. Int. J. Neuropsychopharmacol. (2011) [Pubmed]
  2. Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. Montgomery, S.A., Fava, M., Padmanabhan, S.K., Guico-Pabia, C.J., Tourian, K.A. Int. Clin. Psychopharmacol (2009) [Pubmed]
  3. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Montgomery, S.A., Möller, H.J. Int. Clin. Psychopharmacol (2009) [Pubmed]
  4. The under-recognized role of dopamine in the treatment of major depressive disorder. Montgomery, S.A. Int. Clin. Psychopharmacol (2008) [Pubmed]
  5. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Montgomery, S., Chatamra, K., Pauer, L., Whalen, E., Baldinetti, F. Br. J. Psychiatry (2008) [Pubmed]
  6. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. Montgomery, S.A. CNS. Spectr (2008) [Pubmed]
  7. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Montgomery, S.A., Kasper, S. Int. Clin. Psychopharmacol (2007) [Pubmed]
  8. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Montgomery, S.A., Baldwin, D.S., Blier, P., Fineberg, N.A., Kasper, S., Lader, M., Lam, R.W., Lépine, J.P., Möller, H.J., Nutt, D.J., Rouillon, F., Schatzberg, A.F., Thase, M.E. Int. Clin. Psychopharmacol (2007) [Pubmed]
  9. Why do we need new and better antidepressants?. Montgomery, S.A. Int. Clin. Psychopharmacol (2006) [Pubmed]
  10. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. Montgomery, S.A., Tobias, K., Zornberg, G.L., Kasper, S., Pande, A.C. J. Clin. Psychiatry (2006) [Pubmed]
  11. Escitalopram versus venlafaxine XR in the treatment of depression. Montgomery, S.A., Andersen, H.F. Int. Clin. Psychopharmacol (2006) [Pubmed]
  12. Pregabalin for the treatment of generalised anxiety disorder. Montgomery, S.A. Expert. Opin. Pharmacother (2006) [Pubmed]
  13. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. Montgomery, S.A., Nil, R., Dürr-Pal, N., Loft, H., Boulenger, J.P. J. Clin. Psychiatry (2005) [Pubmed]
  14. Antidepressants and seizures: emphasis on newer agents and clinical implications. Montgomery, S.A. Int. J. Clin. Pract. (2005) [Pubmed]
  15. Venlafaxine versus placebo in the preventive treatment of recurrent major depression. Montgomery, S.A., Entsuah, R., Hackett, D., Kunz, N.R., Rudolph, R.L. J. Clin. Psychiatry (2004) [Pubmed]
  16. A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Montgomery, S.A., Huusom, A.K., Bothmer, J. Neuropsychobiology (2004) [Pubmed]
  17. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Montgomery, S.A., Kennedy, S.H., Burrows, G.D., Lejoyeux, M., Hindmarch, I. Int. Clin. Psychopharmacol (2004) [Pubmed]
  18. ECNP Consensus Meeting, March 2003. Guidelines for the investigation of efficacy in social anxiety disorder. Montgomery, S.A., Lecrubier, Y., Baldwin, D.S., Kasper, S., Lader, M., Nil, R., Stein, D., Van Ree, J.M. Eur. Neuropsychopharmacol (2004) [Pubmed]
  19. The antidepressant efficacy of reboxetine in patients with severe depression. Montgomery, S., Ferguson, J.M., Schwartz, G.E. J. Clin. Psychopharmacol (2003) [Pubmed]
  20. Meta-analysis of double blind randomized controlled clinical trials of acetyl-L-carnitine versus placebo in the treatment of mild cognitive impairment and mild Alzheimer's disease. Montgomery, S.A., Thal, L.J., Amrein, R. Int. Clin. Psychopharmacol (2003) [Pubmed]
  21. Selecting methodologies for the evaluation of differences in time to response between antidepressants. Montgomery, S.A., Bech, P., Blier, P., Möller, H.J., Nierenberg, A.A., Pinder, R.M., Quitkin, F.M., Reimitz, P.E., Rosenbaum, J.F., Rush, A.J., Stassen, H.H., Thase, M.E. J. Clin. Psychiatry (2002) [Pubmed]
  22. Dopaminergic deficit and the role of amisulpride in the treatment of mood disorders. Montgomery, S.A. Int. Clin. Psychopharmacol (2002) [Pubmed]
 
WikiGenes - Universities